Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section

Size: px
Start display at page:

Download "Report generated from BNF provided by FormularyComplete ( Accessed TA Number. Title Formulary Status Section"

Transcription

1 Report generated from BNF provided by FormularyComplete ( Accessed Title Formulary Status Section TA Number TA Link Annotation ABCIXIMAB 2.9 Antiplatelet drugs This drug is not used by this Trust as we use an alternative medicine positively appraised by NICE Actilyse Adalat Retard Adenocor ADENOSINE ADRENALINE/EPINEPHRINE Aldomet Aldosterone antagonists 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs->alteplase blockers->nifedipine->modified release arrhythmias->supraventricular arrhythmias->adenosine arrhythmias->supraventricular arrhythmias 2.7 Sympathomimetics->2.7.3 Cardiopulmonary resuscitation 2.5 Hypertension and heart failure->2.5.2 Centrally acting antihypertensive drugs->methyldopa 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists Alpha-adrenoceptor blocking drugs 2.5 Hypertension and heart failure ALTEPLASE 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs TA264 Amias affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists->candesartan CILEXETIL First line Angiotensin 2 receptor antagonist for the treatment of Congestive Cardiac Failure. Amiloride 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists->amiloride HYDROCHLORIDE

2 AMILORIDE HYDROCHLORIDE 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists Amiodarone arrhythmias->supraventricular and ventricular arrhythmias->amiodarone HYDROCHLORIDE AMIODARONE HYDROCHLORIDE arrhythmias->supraventricular and ventricular arrhythmias AMLODIPINE blockers Amlodipine blockers->amlodipine Angiotensin-converting enzyme inhibitors affecting the renin-angiotensin system Angiotensin-II receptor antagonists affecting the renin-angiotensin system Angiox Parenteral anticoagulants->hirudins->bivalirudin This drug is not used by this Trust as we use an alternative medicine positively appraised by NICE. Anti-arrhythmic drugs Anticoagulants and protamine Antifibrinolytic drugs and haemostatics Antiplatelet drugs Apixaban anticoagulants NICE TA275 recommends apixaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease. APIXABAN anticoagulants->apixaban TA245 NICE TA275 recommends apixaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease. APIXABAN anticoagulants->apixaban TA341 NICE TA275 recommends apixaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease. APIXABAN anticoagulants->apixaban TA275 NICE TA275 recommends apixaban as a possible treatment to prevent stroke and systemic embolism in some people with atrial fibrillation without underlying heart valve disease.

3 Apresoline 2.5 Hypertension and heart failure->2.5.1 Vasodilator antihypertensive drugs->hydralazine HYDROCHLORIDE Aprovel affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists->irbesartan Alternative to losartan in hypertension (particularly in hypertensive microalbuminuria/nephropathy). First line treatment for Microalbuminuria/Proteinuria (early and late nephropathy/diabetic and non-diabetic). Asasantin Retard 2.9 Antiplatelet drugs->dipyridamole->with aspirin Aspirin 2.9 Antiplatelet drugs->aspirin (antiplatelet) Aspirin EC tablets are non-formulary ASPIRIN (antiplatelet) 2.9 Antiplatelet drugs ATENOLOL drugs Atenolol BENDROFLUMETHIAZIDE Beta-adrenoceptor blocking drugs Beta-Cardone Betaloc drugs->atenolol 2.2 Diuretics->2.2.1 Thiazides and related diuretics drugs->sotalol HYDROCHLORIDE drugs->metoprolol TARTRATE BEZAFIBRATE drugs->fibrates Bezafibrate Bezalip drugs->fibrates->bezafibrate drugs->fibrates->bezafibrate Bile acid sequestrants drugs BISOPROLOL FUMARATE drugs For use in heart failure BIVALIRUDIN Parenteral anticoagulants->hirudins TA230 This drug is not used by this Trust as we use an alternative medicine positively appraised by NICE. Blood-related products 2.11 Antifibrinolytic drugs and haemostatics

4 Brilique 2.9 Antiplatelet drugs->ticagrelor Approved for use in ACS patients with a Tropinin Positive event undergoing an invasive strategy with a consultant cardiologist only as prescriber NICE TA236 Acute Coronary Syndromes - Recommended combined with low-dose aspirin for up to a year for treatment for specified people with ACS. BUMETANIDE 2.2 Diuretics->2.2.2 Loop diuretics Bumetanide 2.2 Diuretics->2.2.2 Loop diuretics->bumetanide Calcium-channel blockers other antianginal drugs CANDESARTAN CILEXETIL affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists First line Angiotensin 2 receptor antagonist for the treatment of Congestive Cardiac Failure. Capoten affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors->captopril CAPTOPRIL affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors Captopril affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors->captopril Cardiac glycosides 2.1 Positive inotropic drugs Cardicor drugs->bisoprolol FUMARATE For use in heart failure Cardiopulmonary resuscitation 2.7 Sympathomimetics Cardura 2.5 Hypertension and heart failure->2.5.4 Alpha-adrenoceptor blocking drugs->doxazosin CARVEDILOL drugs For use in heart failure Carvedilol drugs->carvedilol For use in heart failure Centrally acting antihypertensive drugs 2.5 Hypertension and heart failure

5 CHLORTALIDONE 2.2 Diuretics->2.2.1 Thiazides and related diuretics To be used in accordance with NICE guidelines Clexane Parenteral anticoagulants->low molecular weight heparins->enoxaparin SODIUM CLOPIDOGREL 2.9 Antiplatelet drugs TA210 Avoid concomitant use of Omeprazole and esomeprazole. COLESTYRAMINE drugs->bile acid sequestrants Coracten XL blockers->nifedipine->modified release The D&T committee has agreed that Coracten XL should be used in place of Adalat LA Cozaar affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists->losartan POTASSIUM First line Angiotensin 2 receptor antagonist for the treatment of hypertension (especially in LVH). Alternative to Irbesartan in Microalbuminuria /Proteinuria (established nephropathy in hypertensive diabetics +/- LVH). Cyklokapron 2.11 Antifibrinolytic drugs and haemostatics->tranexamic ACID Dabigatran etexilate anticoagulants Approved for Haematology use only to be used in Secondary Care for a target group of patients reacting to warfarin. NICE TA249 Atrial Fibrillation - a recommended option for AF patients with risk factors to prevent stroke and embolism DABIGATRAN ETEXILATE anticoagulants->dabigatran etexilate TA249 Approved for Haematology use only to be used in Secondary Care for a target group of patients reacting to warfarin. NICE TA249 Atrial Fibrillation - a recommended option for AF patients with risk factors to prevent stroke and embolism DABIGATRAN ETEXILATE anticoagulants->dabigatran etexilate TA157 Approved for Haematology use only to be used in Secondary Care for a target group of patients reacting to warfarin. NICE TA249 Atrial Fibrillation - a recommended option for AF patients with risk factors to prevent stroke and embolism DABIGATRAN ETEXILATE anticoagulants->dabigatran etexilate TA327 Approved for Haematology use only to be used in Secondary Care for a target group of patients reacting to warfarin. NICE TA249 Atrial Fibrillation - a recommended option for AF patients with risk factors to prevent stroke and embolism DANAPAROID SODIUM Parenteral anticoagulants->heparinoids Approved as an alternative anticoagulant in patients with Heparin-Induced Thrombocytopenia (HIT). DIGOXIN 2.1 Positive inotropic drugs->2.1.1 Cardiac glycosides Digoxin 2.1 Positive inotropic drugs->2.1.1 Cardiac glycosides->digoxin

6 Digoxin-specific antibody DILTIAZEM HYDROCHLORIDE 2.1 Positive inotropic drugs->2.1.1 Cardiac glycosides blockers DIPYRIDAMOLE 2.9 Antiplatelet drugs TA210 Dipyridamole 2.9 Antiplatelet drugs->dipyridamole DISOPYRAMIDE Disopyramide Diuretics arrhythmias->supraventricular and ventricular arrhythmias arrhythmias->supraventricular and ventricular arrhythmias->disopyramide Diuretics with potassium 2.2 Diuretics DOBUTAMINE 2.7 Sympathomimetics->2.7.1 Inotropic sympathomimetics Dopamine 2.7 Sympathomimetics->2.7.1 Inotropic sympathomimetics->dopamine HYDROCHLORIDE DOPAMINE HYDROCHLORIDE 2.7 Sympathomimetics->2.7.1 Inotropic sympathomimetics Doralese 2.5 Hypertension and heart failure->2.5.4 Alpha-adrenoceptor blocking drugs->indoramin DOXAZOSIN 2.5 Hypertension and heart failure->2.5.4 Alpha-adrenoceptor blocking drugs DRONEDARONE arrhythmias->supraventricular arrhythmias TA197 NICE TA197 Atrial Fibrillation - A recommended option for some people with non-permanent atrial fibrillation. Drugs affecting the renin-angiotensin system 2.5 Hypertension and heart failure Drugs for arrhythmias 2.3 Anti-arrhythmic drugs

7 Efient 2.9 Antiplatelet drugs->prasugrel NICE TA182 Acute Coronary Syndrome - A recommended option with aspirin for patients undergoing PCI in specific circumstances. Hertfordshire Medicines Mangement Committee (HMMC) Sept Green Status - Recommended for restricted use in specific subgoups in secondary and primary care for ACS (in combination with aspirin for the prevention of atherosclerotic events). Elantan LA other antianginal drugs->2.6.1 Nitrates->ISOSORBIDE MONONITRATE->Modified release Eliquis anticoagulants->apixaban->apixaban Included on Anticoagulant Prescription approved at APC 15/05/12 ENOXAPARIN SODIUM Parenteral anticoagulants->low molecular weight heparins EPHEDRINE HYDROCHLORIDE 2.7 Sympathomimetics->2.7.2 Vasoconstrictor sympathomimetics Ephedrine Hydrochloride 2.7 Sympathomimetics->2.7.2 Vasoconstrictor sympathomimetics->ephedrine HYDROCHLORIDE EPLERENONE 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists->aldosterone antagonists Consultant cardiologists initiation Epoprostenol Parenteral anticoagulants EPOPROSTENOL Parenteral anticoagulants->epoprostenol EPTIFIBATIDE 2.9 Antiplatelet drugs Ezetimibe drugs NICE TA132 Hypercholesterolaemia - A recommended option for heterozygous-familial and non-familial hypercholesterolaemia with a statin if cholesterol not low enough, or as monotherapy if a statin is unsuitable. EZETIMIBE drugs->ezetimibe TA132 NICE TA132 Hypercholesterolaemia - A recommended option for heterozygous-familial and non-familial hypercholesterolaemia with a statin if cholesterol not low enough, or as monotherapy if a statin is unsuitable.

8 Ezetrol drugs->ezetimibe->ezetimibe NICE TA132 Hypercholesterolaemia - A recommended option for heterozygous-familial and non-familial hypercholesterolaemia with a statin if cholesterol not low enough, or as monotherapy if a statin is unsuitable. Fibrates drugs Fibrinolytic drugs Flolan 2.10 Stable angina, acute coronary syndromes, and fibrinolysis Parenteral anticoagulants->epoprostenol->epoprostenol FUROSEMIDE 2.2 Diuretics->2.2.2 Loop diuretics Furosemide 2.2 Diuretics->2.2.2 Loop diuretics->furosemide GLYCERYL TRINITRATE other antianginal drugs->2.6.1 Nitrates Glyceryl Trinitrate other antianginal drugs->2.6.1 Nitrates->GLYCERYL TRINITRATE->Short-acting tablets and sprays Heparin Parenteral anticoagulants Heparin flushes Parenteral anticoagulants Heparinoids Parenteral anticoagulants Hirudins Parenteral anticoagulants Hydralazine 2.5 Hypertension and heart failure->2.5.1 Vasodilator antihypertensive drugs->hydralazine HYDROCHLORIDE HYDRALAZINE HYDROCHLORIDE 2.5 Hypertension and heart failure->2.5.1 Vasodilator antihypertensive drugs Hygroton 2.2 Diuretics->2.2.1 Thiazides and related diuretics->chlortalidone To be used in accordance with NICE guidelines Hypertension and heart failure

9 Ikorel INDORAMIN Innohep other antianginal drugs->2.6.3 Other antianginal drugs->nicorandil 2.5 Hypertension and heart failure->2.5.4 Alpha-adrenoceptor blocking drugs Parenteral anticoagulants->low molecular weight heparins->tinzaparin SODIUM Inotropic sympathomimetics 2.7 Sympathomimetics Inspra 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists->aldosterone antagonists->eplerenone Consultant Cardiologist initiation Integrilin 2.9 Antiplatelet drugs->eptifibatide IRBESARTAN affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists Alternative to losartan in hypertension (particularly in hypertensive microalbuminuria/nephropathy). First line treatment for Microalbuminuria/Proteinuria (early and late nephropathy/diabetic and non-diabetic). ISOSORBIDE MONONITRATE other antianginal drugs->2.6.1 Nitrates Isosorbide Mononitrate other antianginal drugs->2.6.1 Nitrates->ISOSORBIDE MONONITRATE Istin blockers->amlodipine IVABRADINE other antianginal drugs->2.6.3 Other antianginal drugs TA267 ' LABETALOL HYDROCHLORIDE drugs Lanoxin-PG Lanoxin Lasix 2.1 Positive inotropic drugs->2.1.1 Cardiac glycosides->digoxin 2.1 Positive inotropic drugs->2.1.1 Cardiac glycosides->digoxin 2.2 Diuretics->2.2.2 Loop diuretics->furosemide

10 Lidocaine arrhythmias->ventricular arrhythmias->lidocaine HYDROCHLORIDE LIDOCAINE HYDROCHLORIDE arrhythmias->ventricular arrhythmias Lipid-regulating drugs Lipostat drugs->statins->pravastatin SODIUM The D&T committee (13/03/06) agreed that patients on simvastatin prone to chest infections, in the view of the Respiratory Physician, and in need of macrolide antibiotics, should have their simvastatin changed to pravastatin. LISINOPRIL affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors Local sclerosants Longer-acting formulations blockers->diltiazem HYDROCHLORIDE Loniten 2.5 Hypertension and heart failure->2.5.1 Vasodilator antihypertensive drugs->minoxidil Loop diuretics 2.2 Diuretics Lopresor drugs->metoprolol TARTRATE LOSARTAN POTASSIUM affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists First line Angiotensin 2 receptor antagonist for the treatment of hypertension (especially in LVH). Alternative to Irbesartan in Microalbuminuria /Proteinuria (established nephropathy in hypertensive diabetics +/- LVH). Low molecular weight heparins Parenteral anticoagulants MANNITOL 2.2 Diuretics->2.2.5 Osmotic diuretics Mannitol Metalyse METARAMINOL 2.2 Diuretics->2.2.5 Osmotic diuretics->mannitol 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs->tenecteplase 2.7 Sympathomimetics->2.7.2 Vasoconstrictor sympathomimetics

11 Metaraminol METHYLDOPA Methyldopa METOLAZONE 2.7 Sympathomimetics->2.7.2 Vasoconstrictor sympathomimetics->metaraminol 2.5 Hypertension and heart failure->2.5.2 Centrally acting antihypertensive drugs 2.5 Hypertension and heart failure->2.5.2 Centrally acting antihypertensive drugs->methyldopa 2.2 Diuretics->2.2.1 Thiazides and related diuretics METOPROLOL TARTRATE drugs Metoprolol Tartrate drugs->metoprolol TARTRATE Minijet Lignocaine arrhythmias->ventricular arrhythmias->lidocaine HYDROCHLORIDE MINOXIDIL 2.5 Hypertension and heart failure->2.5.1 Vasodilator antihypertensive drugs Modified release drugs->propranolol HYDROCHLORIDE Modified release other antianginal drugs->2.6.1 Nitrates->ISOSORBIDE MONONITRATE Modified release blockers->nifedipine Unlicensed use of nifedipine as a tocolyic agent currently under review. Unlicensed use needs to be aknowledged by the Trust Board. Modified release blockers->verapamil HYDROCHLORIDE Modified release 2.9 Antiplatelet drugs->dipyridamole Modified release drugs->fibrates->bezafibrate Multaq arrhythmias->supraventricular arrhythmias->dronedarone NICE TA197 Atrial Fibrillation - A recommended option for some people with non-permanent atrial fibrillation.

12 Naftidrofuryl other antianginal drugs->2.6.4 Peripheral vasodilators and related drugs->naftidrofuryl OXALATE NAFTIDROFURYL OXALATE other antianginal drugs->2.6.4 Peripheral vasodilators and related drugs TA223 NICORANDIL other antianginal drugs->2.6.3 Other antianginal drugs Nicorandil other antianginal drugs->2.6.3 Other antianginal drugs->nicorandil NIFEDIPINE blockers The unlicensed use of Nifedipine as a tocolytic agent is currently under review. (D&T Minutes 14/07/03) NIMODIPINE blockers Nimotop blockers->nimodipine Nitrates other antianginal drugs Nitrates, calcium-channel blockers, and other antianginal drugs Nitrocine other antianginal drugs->2.6.1 Nitrates->GLYCERYL TRINITRATE->Parenteral preparations NORADRENALINE/NOREPINEPHRINE 2.7 Sympathomimetics->2.7.2 Vasoconstrictor sympathomimetics Oral anticoagulants 2.8 Anticoagulants and protamine

13 Orgaran Parenteral anticoagulants->heparinoids->danaparoid SODIUM Approved as an alternative anticoagulant in patients with Heparin-Induced Thrombocytopenia (HIT). Osmotic diuretics 2.2 Diuretics Other antianginal drugs other antianginal drugs Parenteral anticoagulants 2.8 Anticoagulants and protamine Parenteral preparations Peripheral vasodilators and related drugs other antianginal drugs->2.6.1 Nitrates->GLYCERYL TRINITRATE other antianginal drugs Persantin 2.9 Antiplatelet drugs->dipyridamole Persantin Retard 2.9 Antiplatelet drugs->dipyridamole->modified release Phaeochromocytoma 2.5 Hypertension and heart failure->2.5.4 Alpha-adrenoceptor blocking drugs PHENTOLAMINE MESILATE 2.5 Hypertension and heart failure->2.5.4 Alpha-adrenoceptor blocking drugs->phaeochromocytoma Phenylephrine 2.7 Sympathomimetics->2.7.2 Vasoconstrictor sympathomimetics->phenylephrine HYDROCHLORIDE Used for treating hypotension during caesarean section. Ephedrine injection used for treating hypotension with bradycardia during caesarean section. PHENYLEPHRINE HYDROCHLORIDE 2.7 Sympathomimetics->2.7.2 Vasoconstrictor sympathomimetics Used for treating hypotension during caesarean section. Ephedrine injection used for treating hypotension with bradycardia during caesarean section. Plavix 2.9 Antiplatelet drugs->clopidogrel Positive inotropic drugs Potassium-sparing diuretics and aldosterone antagonists Potassium-sparing diuretics with other diuretics 2.2 Diuretics 2.2 Diuretics

14 Pradaxa anticoagulants->dabigatran etexilate->dabigatran ETEXILATE PRASUGREL 2.9 Antiplatelet drugs TA317 NICE TA182 Acute Coronary Syndrome - A recommended option with aspirin for patients undergoing PCI in specific circumstances. Hertfordshire Medicines Mangement Committee (HMMC) Sept Green Status - Recommended for restricted use in specific subgoups in secondary and primary care for ACS (in combination with aspirin for the prevention of atherosclerotic events). Pravastatin drugs->statins->pravastatin SODIUM The D&T committee (13/03/06) agreed that patients on simvastatin prone to chest infections, in the view of the Respiratory Physician, and in need of macrolide antibiotics, should have their simvastatin changed to pravastatin. PRAVASTATIN SODIUM drugs->statins The D&T committee (13/03/06) agreed that patients on simvastatin prone to chest infections, in the view of the Respiratory Physician, and in need of macrolide antibiotics, should have their simvastatin changed to pravastatin. Praxilene other antianginal drugs->2.6.4 Peripheral vasodilators and related drugs->naftidrofuryl OXALATE Procoralan other antianginal drugs->2.6.3 Other antianginal drugs->ivabradine ' Propranolol drugs->propranolol HYDROCHLORIDE PROPRANOLOL HYDROCHLORIDE drugs Protamine sulfate 2.8 Anticoagulants and protamine RAMIPRIL affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors Ramipril affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors->ramipril Ranexa other antianginal drugs->2.6.3 Other antianginal drugs->ranolazine Consultant initiation only. Hospital only initiation.. Review by consultant in 4-6 weeks for further treatment and/or dose titration. Refer to GP only if patient stable and not requiring dose titration

15 Rapilysin 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs->reteplase This drug is not used by the Trust as we use an alternative medicine positively appraised by NICE. ReoPro 2.9 Antiplatelet drugs->abciximab This drug is not used by this Trust as we use an alternative medicine positively appraised by NICE RETEPLASE 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs This drug is not used by the Trust as we use an alternative medicine positively appraised by NICE. Rivaroxaban anticoagulants RIVAROXABAN anticoagulants->rivaroxaban TA256 RIVAROXABAN anticoagulants->rivaroxaban TA170 RIVAROXABAN anticoagulants->rivaroxaban TA261 RIVAROXABAN anticoagulants->rivaroxaban TA287 RIVAROXABAN anticoagulants->rivaroxaban TA335 Rythmodan arrhythmias->supraventricular and ventricular arrhythmias->disopyramide Short-acting tablets and sprays other antianginal drugs->2.6.1 Nitrates->GLYCERYL TRINITRATE SIMVASTATIN drugs->statins First line statin Simvastatin drugs->statins->simvastatin First line statin SODIUM NITROPRUSSIDE 2.5 Hypertension and heart failure->2.5.1 Vasodilator antihypertensive drugs Sodium Nitroprusside 2.5 Hypertension and heart failure->2.5.1 Vasodilator antihypertensive drugs->sodium NITROPRUSSIDE SODIUM TETRADECYL SULFATE 2.13 Local sclerosants

16 Sotacor Sotalol drugs->sotalol HYDROCHLORIDE drugs->sotalol HYDROCHLORIDE SOTALOL HYDROCHLORIDE drugs Stable angina, acute coronary syndromes, and fibrinolysis Standard formulations blockers->diltiazem HYDROCHLORIDE Statins drugs Streptase 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs->streptokinase This drug is not used by the Trust as we use an alternative medicine positively appraised by NICE STREPTOKINASE 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs This drug is not used by the Trust as we use an alternative medicine positively appraised by NICE Supraventricular and ventricular arrhythmias arrhythmias Supraventricular arrhythmias arrhythmias Sympathomimetics TENECTEPLASE 2.10 Stable angina, acute coronary syndromes, and fibrinolysis-> Fibrinolytic drugs Tenormin drugs->atenolol Thiazides and related diuretics 2.2 Diuretics TICAGRELOR 2.9 Antiplatelet drugs TA236 Approved for use in ACS patients with a Tropinin Positive event undergoing an invasive strategy with a consultant cardiologist only as prescriber. NICE TA236 Acute Coronary Syndromes - Recommended combined with low-dose aspirin for up to a year for treatment for specified people with ACS. Tildiem LA blockers->diltiazem HYDROCHLORIDE->Longer-acting formulations

17 Tildiem Retard TINZAPARIN SODIUM blockers->diltiazem HYDROCHLORIDE->Longer-acting formulations Parenteral anticoagulants->low molecular weight heparins TIROFIBAN 2.9 Antiplatelet drugs This drug is not used by the Trust as we use an alternative medicine positively appraised by NICE. TRANEXAMIC ACID 2.11 Antifibrinolytic drugs and haemostatics Transdermal preparations Transiderm-Nitro Tritace other antianginal drugs->2.6.1 Nitrates->GLYCERYL TRINITRATE other antianginal drugs->2.6.1 Nitrates->GLYCERYL TRINITRATE->Transdermal preparations affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors->ramipril Vasoconstrictor sympathomimetics 2.7 Sympathomimetics Vasodilator antihypertensive drugs 2.5 Hypertension and heart failure Ventricular arrhythmias Verapamil VERAPAMIL HYDROCHLORIDE Warfarin WARFARIN SODIUM arrhythmias blockers->verapamil HYDROCHLORIDE blockers anticoagulants->coumarins and phenindione->warfarin SODIUM anticoagulants->coumarins and phenindione

18 With aspirin 2.9 Antiplatelet drugs->dipyridamole Xarelto anticoagulants->rivaroxaban->rivaroxaban Zestril affecting the renin-angiotensin system-> Angiotensin-converting enzyme inhibitors->lisinopril Zocor drugs->statins->simvastatin First line statin Aldactone 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists->aldosterone antagonists->spironolactone use - see BNF indications ALISKIREN affecting the renin-angiotensin system-> Renin inhibitors To be prescribed by a consultant cardiologist only and used as a 4th line treatment in patients whose blood pressure was still above target and taking an ACEI/ARB, Calcium Channel Blocker and a diuretic (ACD NICE Guidelines in Hypertension 2006). Patients should be actively followed up ATORVASTATIN drugs->statins Second choice - Alternative to simvastatin or pravastatin. In appropriate circumstances, atorvastatin doses of 10 and 20 mg daily to be changed to Simvastatin 40 mg daily (See separate Statin switch Guidelines). Crestor drugs->statins->rosuvastatin Prescribed by consultant cardiologist only FACTOR VIIa (RECOMBINANT) 2.11 Antifibrinolytic drugs and haemostatics->blood-related products Consultant haematologist use only. Funding should be agreed. Flecainide arrhythmias->supraventricular and ventricular arrhythmias->flecainide ACETATE Flecainide available on a prescription signed by a consultant cardiologist only. FLECAINIDE ACETATE arrhythmias->supraventricular and ventricular arrhythmias Flecainide available on a prescription signed by a consultant cardiologist only. Lipitor drugs->statins->atorvastatin Second choice - Alternative to simvastatin or pravastatin. In appropriate circumstances, atorvastatin doses of 10 and 20 mg daily to be changed to Simvastatin 40 mg daily (See separate Statin switch Guidelines). Micardis affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists->telmisartan Approved as first line ARB in treating hypertension in the elderly.

19 Pletal other antianginal drugs->2.6.4 Peripheral vasodilators and related drugs->cilostazol Available on a consultant signature only. Patients are to be reviewed in clinic after four months. RANOLAZINE other antianginal drugs->2.6.3 Other antianginal drugs Consultant initiation only. Review by consultant in 4-6 weeks for further treatment and/or dose titration. Refer to GP only if patient stable and not requiring dose titration Rasilez affecting the renin-angiotensin system-> Renin inhibitors->aliskiren Renin inhibitors affecting the renin-angiotensin system To be prescribed by a consultant cardiologist only and used as a 4th line treatment in patients whose blood pressure was still above target and taking an ACEI/ARB, Calcium Channel Blocker and a diuretic (ACD NICE Guidelines in Hypertension 2006). Patients should be actively followed up ROSUVASTATIN drugs->statins Prescribed by consultant cardiologist only SPIRONOLACTONE 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists->aldosterone antagonists use - See BNF indications Spironolactone 2.2 Diuretics->2.2.3 Potassium-sparing diuretics and aldosterone antagonists->aldosterone antagonists->spironolactone Use - See BNF indications Tambocor arrhythmias->supraventricular and ventricular arrhythmias->flecainide ACETATE Flecainide available on a prescription signed by a consultant cardiologist only. TELMISARTAN affecting the renin-angiotensin system-> Angiotensin-II receptor antagonists Approved as first line ARB in treating hypertension in the elderly.

Chapter / Section / Drug

Chapter / Section / Drug 2 Cardiovascular System 2.1 Positive inotropic drugs Digoxin Digoxin specific antibody ( DigiFab ) 2.2 Diuretics 2.2.1 Thiazides and related diuretics Indapamide (1 st Line) Bendroflumethiazide Metolazone

More information

Chapter 2 ~ Cardiovascular system

Chapter 2 ~ Cardiovascular system Chapter 2 ~ Cardiovascular System: General Section 1 of 6 Chapter 2 ~ Cardiovascular system 2.1 Positive inotropic drugs 2.1.1 Cardiac glycosides DIGOXIN 2.2 Diuretics Elixir 50micrograms in 1ml Injection

More information

5mg/5mL Liquid 25mg Tablets 50mg Tablets 100mg Tablets 50mg/5mL Suspension Special standardise strength 25mg Tablets

5mg/5mL Liquid 25mg Tablets 50mg Tablets 100mg Tablets 50mg/5mL Suspension Special standardise strength 25mg Tablets Chapter 2- Cardiovascular Category Drug name Strength / dose / form BCU 2.1 Positive Inotropic drugs 2.1.1 Cardiac Digoxin 62.5 microgram Tablets Glycosides 125 microgram Tablets 250 microgram Tablets

More information

Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices

Chapter 2 - Cardiovascular System. Primary Care Prescribing Formulary - Preferred Drug Choices Chapter 2 - Cardiovascular System Primary Care Prescribing Formulary - Preferred Drug Choices Drug group Drug choice Comments/notes Cardiac glycosides Thiazide diuretics Loop diuretics Aldosterone antagonist

More information

2. Cardiovascular System

2. Cardiovascular System 1 2. Cardiovascular System 2.1 - Positive inotropic drugs 2.1.1 Cardiac glycosides Digoxin H - Digoxin specific antibody (Digifab ) Digoxin is indicated for rate control in atrial fibrillation and as add-on

More information

2. Cardiovascular System

2. Cardiovascular System 1 2. Cardiovascular System 2.1 - Positive inotropic drugs 2.1.1 Cardiac glycosides Digoxin H - Digoxin specific antibody (Digifab ) Digoxin is indicated for rate control in atrial fibrillation and as add-on

More information

Cardiac Medications At A Glance

Cardiac Medications At A Glance Cardiac Medications At A Glance 1) Anticoagulants (Also known as Blood Thinners.) Dalteparin (Fragmin), Danaparoid (Orgaran) Enoxaparin (Lovenox) Heparin (various) Tinzaparin (Innohep) Warfarin (Coumadin)

More information

Beta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol.

Beta-blockers. Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol. Drugs of CVS Beta-blockers Atenolol. Propranolol. Bisoprolol. Metoprolol. Labetalol. Carvedilol. Atenolol.cardioselective Propranolol, nonselective Bisoprolol, cardioselective Metoprolol Carvedilol, alpha

More information

Cardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist

Cardiovascular Risk Reduction in Diabetic Mellitus. Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist Cardiovascular Risk Reduction in Diabetic Mellitus Presenter: Dr. Martin N. Wanyoike MB.CHB., M. Med.(internal med) Physician / Cardiologist Cardiovascular Risk Reduction in Diabetic Mellitus Disclosures

More information

Back. Thiazide diuretics Drug Indication Formulation Notes on prescribing Bendroflumethiazide Hypertension, oedema Tablets

Back. Thiazide diuretics Drug Indication Formulation Notes on prescribing Bendroflumethiazide Hypertension, oedema Tablets Cardiovascular System General information Diuretics and related drugs Anti-arrhythmic drugs Drugs affecting the renin - angiotensin system Calcium channel blockers α-adrenoreceptor blocking drugs β-adrenoreceptor

More information

ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR

ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS ALISKIREN 150MG TABLET RASILAZ RENIN INHIBITOR S/N ME OF MEDICATIONS BRANDED/GENERIC DRUG CLASS * UNIT PRICE RANGE (SGD$) 1 ACEBUTOLOL HCL 100MG CAPSULE SECTRAL BETA BLOCKERS 0.50 2 ACEBUTOLOL HCL 100MG TABLET GENERIC BETA BLOCKERS 0.33 3 ALISKIREN

More information

Sandwell and West Birmingham Hospitals NHS Trust

Sandwell and West Birmingham Hospitals NHS Trust Sandwell and West Birmingham Hospitals NHS Trust Sandwell and West Birmingham Clinical Commissioning Group The drugs contained in the formulary of Sandwell and West Birmingham Hospitals Trust are listed

More information

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

CARDIAC REHABILITATION PROGRAMME:- MEDICATION CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to

More information

Chapter 2 Cardiovascular System

Chapter 2 Cardiovascular System Chapter 2 page number 1 Chapter 2 Cardiovascular System First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions) in both primary

More information

2.1.2 CARDIAC GLYCOSIDES

2.1.2 CARDIAC GLYCOSIDES 2.1.2 CARDIAC GLYCOSIDES Digoxin 62.5, 125, 250microgram tablets 50 micrograms/ml elixir 100 micrograms/ml injection (paed) (special) 500 micrograms/2ml injection The dose of digoxin has to be tailored

More information

Management of Hypertension

Management of Hypertension Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal

More information

Cardiovascular system

Cardiovascular system Contents: Cardiovascular system 1. Hypertension 2 2. Hypertensive crises 4 3. Heart failure acute 5 4. Heart failure (chronic management) 6 5. Acute chest pain, angina and acute coronary syndromes (including

More information

Cardiovascular system

Cardiovascular system Cardiovascular system A. Positive inotropic drugs Drug classifications: Cardiac glycosides - Digoxin, Digitoxin Phosphodiesterase inhibitors - Enoximone, milrinone Inotropic sympathomimetics - dobutamine,

More information

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.

Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:

More information

Medications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy.

Medications. Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy. Medications Your prescriptions can be filled by your home pharmacy or by the Michigan Medicine Taubman Center outpatient pharmacy. What do I need to know about medications after my heart attack? When you

More information

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting

More information

Information in these slides is used with permission from St. Mary s Cardiac Rehab

Information in these slides is used with permission from St. Mary s Cardiac Rehab Information in these slides is used with permission from St. Mary s Cardiac Rehab Prescription Pointers Heart Medications Questions!! 2-4% of patients who visit ER s have experienced a medication misadventure

More information

Hypertension (JNC-8)

Hypertension (JNC-8) Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint

More information

Contents: 1. Hypertension

Contents: 1. Hypertension Contents: Cardiovascular system Medicines Formulary 1. Hypertension 2 2. Hypertensive crises 4 3. Heart failure acute 5 4. Heart failure (chronic management) 6 5. Acute chest pain, angina and acute coronary

More information

Cardiovascular drugs

Cardiovascular drugs chapter 13 Cardiovascular drugs Cardiovascular drugs act on the heart or blood vessels to control the cardiovascular system. They are used to treat a variety of conditions from hypertension to chronic

More information

Antihypertensive drugs SUMMARY Made by: Lama Shatat

Antihypertensive drugs SUMMARY Made by: Lama Shatat Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone

More information

Medications and your Heart. RBCH Foundation Trust

Medications and your Heart. RBCH Foundation Trust Medications and your Heart RBCH Foundation Trust Today I will try and cover Confusing cocktail of drugs? What are they for? How do I take them? What if I forget to take them? What are common side effects?

More information

Select Preventive Prescription Drugs Jan. 1, 2018

Select Preventive Prescription Drugs Jan. 1, 2018 Select Preventive Prescription Drugs Jan. 1, 2018 In addition to a healthy lifestyle, preventive medications can help you avoid some illnesses and conditions. Zimmer Biomet's medical options Value HSA,

More information

perioperative management of cardiovascular drugs

perioperative management of cardiovascular drugs perioperative management of cardiovascular drugs Dave Pappin and Vanessa Helliwell, Exeter, UK. Email: vanessahelliwell@doctors.org.uk It is estimated that by 2010 cardiovascular disease will be the leading

More information

ASEBP and ARTA TARP Drugs and Reference Price by Categories

ASEBP and ARTA TARP Drugs and Reference Price by Categories ASEBP Pantoprazole Sodium 40 mg (generic) $0.2016 ASEBP Dexlansoprazole 30 mg Dexlansoprazole 60 mg Esomeprazole 10 mg Esomeprazole 20 mg Esomeprazole 40 mg Lansoprazole 15 mg Lansoprazole 30 mg Omeprazole

More information

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%

Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40% Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF

More information

PassAssured's Pharmacy Technician Training Systems. Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC

PassAssured's Pharmacy Technician Training Systems. Medication Review. Cardiovascular Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cardiovascular Drugs Pharmacy Technician Training Systems Passassured, LLC p1 Medication Review, Cardiovascular Drugs Click Here for Glossary Index! Click Here to Print Topic Help File

More information

Comprehensive Drug Information for Smith, John

Comprehensive Drug Information for Smith, John PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive

More information

Antihypertensive drugs: I. Thiazide and other diuretics:

Antihypertensive drugs: I. Thiazide and other diuretics: Clinical assessment of hypertensive patient: You have to take history regarding the presence of other risk factors for CAb like diabetes mellitus, smoking, etc. Take history whether the patient takes medications

More information

12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER)

12.5mg, 25mg, 50mg. 25mg, 50mg. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg. -- $2.81 Acetazolamide (IR, 125mg, 250mg, 500mg (ER) MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 5/9/2017 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 9/15, 2/13, 2/08, 5/07 LOB

More information

TREATMENT OF HYPERTENSION

TREATMENT OF HYPERTENSION TREATMENT OF HYPERTENSION Aim of treatment BP Goals Main items of treatment Lifestyle modification When to start drug Rx Pharmacological therapy 1. Relief of symptoms 2. Prevention of complications and

More information

2 CARDIOVASCULAR SYSTEM

2 CARDIOVASCULAR SYSTEM 2 CARDIOVASCULAR SYSTEM 2.01 THIAZIDE, OSMOTIC & LOOP DIURETICS - THIAZIDES [TD], POTASSIUM SPARING [PSD], LOOP DIURETICS [LD] Frusemide Inj 10mg/ml, 2ml (Lasix) [Furosemide] [LD] Frusemide Tab 40mg (Lasix)

More information

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys

More information

Antihypertensive Agents

Antihypertensive Agents Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,

More information

Chapter 20. Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics

Chapter 20. Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics Chapter 20 Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics Epidemiology and Etiology of Hypertension Primary: Unknown etiology Secondary: Due to known disease process Adversely

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

Heart Failure Clinician Guide JANUARY 2018

Heart Failure Clinician Guide JANUARY 2018 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.

More information

Medicines for Heart Disease

Medicines for Heart Disease Medicines for Heart Disease There are many medicines to treat heart disease. Ask your doctor, nurse, or pharmacist if you have questions about your medicines. Take medicines as directed. Do NOT stop taking

More information

CARDIAC IMAGING QUESTIONNAIRE

CARDIAC IMAGING QUESTIONNAIRE Date of test: / / Month day year Last name First name Middle initial Street address City State Zip code Home phone ( ) - Work phone ( ) - Cell Phone ( ) - Email: Age: Demographics: What is your ethnicity?

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1

More information

Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure.

Hypertension is also an important risk factor in the development of chronic kidney disease and heart failure. Hypertension Hypertension Hypertension is defined as either a sustained systolic blood pressure of greater than 140 mm Hg or a sustained diastolic blood pressure of greater than 90 mm Hg. Hypertension

More information

CHAPTER 2. Knowing YOUR MEDICATIONS. Image: istock.com/bakibg. Knowing Your Medications 23

CHAPTER 2. Knowing YOUR MEDICATIONS. Image: istock.com/bakibg. Knowing Your Medications 23 CHAPTER 2 Knowing YOUR MEDICATIONS Knowing Your Medications 23 Image: istock.com/bakibg MEDICATION Prescription medications help your heart get better and protect you from more harm. People who take their

More information

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic

More information

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit

More information

Cardiovascular Clinical Practice Guideline Pilot Implementation

Cardiovascular Clinical Practice Guideline Pilot Implementation Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high

More information

The ADDITION Study: A study about screening for diabetes. Screening Case Report Form

The ADDITION Study: A study about screening for diabetes. Screening Case Report Form ADDITION Study, Leicester Participant Identification Label: Date: / / The ADDITION Study: A study about screening for diabetes Screening Case Report Form You will need to have the following things done

More information

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.

More information

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine

More information

STANDARD treatment algorithm mmHg

STANDARD treatment algorithm mmHg STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If

More information

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured. Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.

More information

What in the World is Functional Medicine?

What in the World is Functional Medicine? What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They

More information

Section 3, Lecture 2

Section 3, Lecture 2 59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect

More information

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015 Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A 294.3 for use in Northern Ireland) Sep 2015 BNF 1.3.5 Proton pump inhibitors Lansoprazole orodispersible

More information

Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted

Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted Patient Name: Diagnosis: Allergies with reaction type: Chest Pain Acute Coronary Syndrome Version 4 4/10/17 This order set is designed to be used with an admission set or for a patient already admitted

More information

Clinical Teach-Back Cards

Clinical Teach-Back Cards Clinical Teach-Back Cards The Quality Innovation Network - Quality Improvement Organization (QIN-QIO) for Delaware, Louisiana, New Jersey, Pennsylvania and West Virginia The people at Quality Insights

More information

REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION.

REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION. CORONARY ARTERY DISEASE REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION. * REQUEST FOR ANGIO-TENSIN RECEPTOR BLOCKER WILL

More information

Inventory of paediatric therapeutic needs

Inventory of paediatric therapeutic needs 24 April 2013 EMA/PDCO/246339/2013 Human Medicines Development and Evaluation Cardiovascular therapeutic area Agreed by PDCO August 2012 Adopted by PDCO for release for consultation 15-17 August 2012 Start

More information

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood

More information

LESSON ASSIGNMENT. After completing this lesson you will be able to:

LESSON ASSIGNMENT. After completing this lesson you will be able to: LESSON ASSIGNMENT SUBCOURSE MD0806 LESSON 7 Therapeutics III. Antihypertensive Agents. LESSON ASSIGNMENT Paragraphs 7-1--7-12. LESSON OBJECTIVES After completing this lesson you will be able to: 7-1. From

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

Eliquis and plavix combination therapy

Eliquis and plavix combination therapy Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is

More information

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure? Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,

More information

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC

HypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided

More information

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Insert Logo or Org Name Here Primary Care Medical Directive for Hypertension Management Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017 Title:

More information

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations

Dose. Route. Units. Given. Special situations. Dose. Route. Units. Given. Special situations Chapter 3 Cardiology Georgia Woodfield ASPIRIN FONDAPARINUX 300 once only in acute MI 75 in primary/ secondary prevention of thrombus formation and thromboembolic disease or PR; can also be given via nasogastric

More information

Report generated from BNF - NNUH Formulary provided by FormularyComplete (www.pharmpress.com). Accessed

Report generated from BNF - NNUH Formulary provided by FormularyComplete (www.pharmpress.com). Accessed Report generated from BNF - NNUH Formulary provided by FormularyComplete (www.pharmpress.com). Accessed 24 11 2017 This is a live document. Changes may have been made to the formulary since this report

More information

Factors Involved in Poor Control of Risk Factors

Factors Involved in Poor Control of Risk Factors Factors Involved in Poor Control of Risk Factors Patient compliance Clinical inertia Health Care System structure 14781 M Limitations of Formal Studies Selection of patients Recruitment and follow-up alter

More information

Updates in Therapeutics: 2013 Pharmacotherapy Preparatory Review and Recertification Course

Updates in Therapeutics: 2013 Pharmacotherapy Preparatory Review and Recertification Course AMERICAN COLLEGE OF CLINICAL PHARMACY Updates in Therapeutics: 2013 Pharmacotherapy Preparatory Review and Recertification Course POSTTEST ANSWERS SESSION 8 Cardiology I 1. Answer B: NTG intravenously

More information

Hypertension Management - Summary

Hypertension Management - Summary Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)

More information

COPYRIGHTED MATERIAL. Index. Ó 2009 John Wiley & Sons, Ltd

COPYRIGHTED MATERIAL. Index. Ó 2009 John Wiley & Sons, Ltd Index Figures and Tables are indicated by italic page numbers, Boxes by bold numbers. Abbreviations: ACS ¼ acute coronary syndrome; ECG ¼ electrocardiography; MI ¼ myocardial infarction; PCI ¼ percutaneous

More information

12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg

12.5mg, 25mg, 50mg. 25mg, 50mg. 250mg, 500mg, 250mg/5ml. 2.5mg, 5mg, 10mg. 5mg, 10mg, 20mg, 100mg. 25mg MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Blood Pressure P&T DATE: 9/11/2018 THERAPEUTIC CLASS: Cardiovascular Disorders REVIEW HISTORY: 5/17, 9/15, 2/13, 2/08, LOB

More information

Cardiovascular System

Cardiovascular System CHAPTER 2 CARDIOVASCULAR SYSTEM 2.1 Acute stroke NICE CG68 - Diagnosis and initial management of acute stroke and transient ischaemic attack (TIA), July 2008 and NICE TA 210 - Vascular disease clopidogrel

More information

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade

More information

ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut

ANTIHYPERTENSIVES. Assoc. Prof. Bilgen Başgut ANTIHYPERTENSIVES Assoc. Prof. Bilgen Başgut Hypertension Hypertension is a condition in which the blood pressure is persistently higher than normal Hypertension > 140 mmhg > 90 mmhg Systolic Blood Pressure

More information

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples

More information

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention

Cardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention Cardiology Self Learning Package Module 5: Pharmacology: Treatment of Acute Coronary Syndromes, Module 5: Pharmacology: Hyperlipidaemia, Treatment of Acute Coronary Hypertension, Symdrome, Hyperlipidaemia,

More information

REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION.

REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION. CARDIOMYOPATHY REGISTRATION CRITERIA : SPECIALIST INITIATION OF TREATMENT AND FOR ANY SIGNIFICANT INCREASES IN DOSAGES OR ADDITION OF MEDICATION. * REQUEST FOR ANGIO-TENSIN RECEPTOR BLOCKER WILL REQUIRE

More information

Heart failure Management of symptoms and treatment

Heart failure Management of symptoms and treatment 2 Heart failure Management of symptoms and treatment 1 Managing heart failure Contents The Heartbeat Trust is Ireland s national heart failure charity (CHY 5938). It supports specialist clinical and research

More information

Managing IHD and acute Myocardial Infarction

Managing IHD and acute Myocardial Infarction Managing IHD and acute Myocardial Infarction In Ireland- 1 out of every 10 deaths ( 22% of all premature deaths) in 2006 were due to CVD 30,000 15,000 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 Source

More information

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist physician Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI Outcome objectives of the discussion: At the end of the

More information

Additional Standard Generics HSA Preventive Drug List Effective January 1, 2019

Additional Standard Generics HSA Preventive Drug List Effective January 1, 2019 Additional Standard Generics HSA Preventive Drug List Effective January 1, 2019 Employers can elect to include an additional generic HSA Preventive Drug coverage feature with your prescription benefit

More information

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes

More information

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology

8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy

More information

Antihypertensives. Diagnostic category

Antihypertensives. Diagnostic category Measurement of blood pressure At first assessment, take both arms then choose the one with the higher reading. Beware of orthostatic hypotension. Measure BP in sitting position, and repeat after patient

More information

University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D

University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D University of Al Qadisiyah College of Pharmacy Dr. Bassim I Mohammad, MBChB, MSc, Ph.D Cardiovascular Pharmacology 1. Antihypertensives 2. Antianginal 3. Drugs for HF 4. Antiarrythemics 5. Drugs for Hyperlipoproteniemia

More information

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011)

Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) Volume 6; Number 1 January 2012 NICE CLINICAL GUIDELINE 127: HYPERTENSION CLINICAL MANAGEMENT OF PRIMARY HYPERTENSION IN ADULTS (AUGUST 2011) What s new in hypertension? NICE has issued an updated Clinical

More information

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation

More information

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for

More information

11/4/2017. but cocaine toxicity is complex: Pro thrombotic effects Progressive atherosclerosis Ventricular remodeling

11/4/2017. but cocaine toxicity is complex: Pro thrombotic effects Progressive atherosclerosis Ventricular remodeling 2 Learning Objectives ATRIUM Fall Patient Safety Webinar Cardiology Mythbusters: Vol 1 Brent N. Reed, PharmD, BCPS AQ Cardiology Associate Professor, University of Maryland School of Pharmacy This presentation

More information

sympatholytics sympatholytics sympatholytics

sympatholytics sympatholytics sympatholytics sympatholytics sympatholytics sympatholytics CNS-ACTING SYMPATHOPLEGICS Sympathetic brain signals Doesn t affect baroreceptor reflex (no orthostatic hypotension) Methyldopa α-methylne crosses BBB (+) α-adrenoreceptors

More information

Codes for a Medicare claims-based model to predict LVEF class- User Guide

Codes for a Medicare claims-based model to predict LVEF class- User Guide Description and citation: This guide accompanies our manuscript [Desai RJ, Lin KJ, Patorno E, et al. Development and Preliminary Validation of a Medicare Claims Based Model to Predict Left Ventricular

More information

Prescribing Formulary. 6 th Edition October 2009

Prescribing Formulary. 6 th Edition October 2009 Prescribing Formulary 6 th Edition October 2009 Somerset Primary Care Trust - Primary Care Formulary 6th Edition October 2009 Introduction This formulary has been developed and reviewed by the Somerset

More information

Review Protocol Patient information

Review Protocol Patient information Review Protocol Patient information What are information needs of patients with stable angina regarding their condition and its management? Adults with a diagnosis of stable angina including people with

More information

Proposal Relating to the Funding of Certain Pharmaceuticals in DHB Hospitals

Proposal Relating to the Funding of Certain Pharmaceuticals in DHB Hospitals 3 August 2012 Proposal Relating to the Funding of Certain Pharmaceuticals in DHB Hospitals PHARMAC is seeking feedback on a proposal relating to the establishment of a nationallyconsistent list of pharmaceuticals

More information

Volume 5; Number 17 October 2011

Volume 5; Number 17 October 2011 Volume 5; Number 17 October 2011 What s new this month? Dabigatran etexilate (Pradaxa) is evaluated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation

More information